EUVIMEDEUVIMED entdecken
Open Access

The Investigation of Hsp90C‐Terminal Inhibitors Containing Amide Bioisosteres

Eva Amatya, Chitra Subramanian, Reagan Long, Kelli McNamara, Mark S Cohen, Brian S J Blagg iD

ChemMedChem · 16.12.2024 · 19 (24)

DOI: 10.1002/cmdc.202400418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 29.10.2024. Verfasst von Eva Amatya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Warren Family Research Center for Drug Discovery and Development, University of Notre Dame, Notre Dame, Ind…. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Amides, Cell Proliferation, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heat Shock Protein 90 (Hsp90) is responsible for the proper folding and maturation of ~400 client protein substrates, many of which are directly associated with the ten hallmarks of cancer. Hsp90 is a great target for cancer therapy including melanoma, since Hsp90 inhibition can disrupt multiple oncogenic pathways simultaneously. In this study, we report the synthesis and anti‐proliferative activity manifested by a series of Hsp90 C‐terminal inhibitors against mutant BRAF and wild‐type BRAF melanoma cells. Furthermore, we explored structure‐activity relationships (SAR) for the amide moiety of 6 ( B1 ), a novel Hsp90C‐terminal inhibitor via introduction of amide bioisosteres. Compound 6 displayed an IC 50 of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM against SKMel173, SKMel103, SKMel19 and A375 cells, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsAmidesCell ProliferationAntineoplastic AgentsHumansStructure-Activity RelationshipCell Line, TumorDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugProto-Oncogene Proteins B-rafMelanoma

Stichwörter der Autor:innen

Anti-cancerBRAF and MEK mutant resistantC-terminal inhibitorsHeat shock protein 90 (Hsp90)MelanomaNovobiocin derivative

Substanzen

HSP90 Heat-Shock ProteinsAmidesAntineoplastic AgentsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Warren Family Research Center for Drug Discovery and Development, University of Notre Dame, Notre Dame, Indiana, 46556, USA.
  • Cancer Center at Illinois, University of Illinois Urbana-Champaign, Urbana, Illinois, 61801, United States.

ORCID-Profile: Brian S J Blagg

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Amatya, E., Subramanian, C., Long, R., McNamara, K., Cohen, M. S., & Blagg, B. S. J. (2024). The Investigation of Hsp90C‐Terminal Inhibitors Containing Amide Bioisosteres. ChemMedChem, 19(24). https://doi.org/10.1002/cmdc.202400418

Vancouver

Amatya E, Subramanian C, Long R, McNamara K, Cohen MS, Blagg BSJ. The Investigation of Hsp90C‐Terminal Inhibitors Containing Amide Bioisosteres. ChemMedChem. 2024;19(24). doi:10.1002/cmdc.202400418

BibTeX
@article{Amatya2024,
  author = {Amatya, Eva and Subramanian, Chitra and Long, Reagan and McNamara, Kelli and Cohen, Mark S and Blagg, Brian S J},
  title = {The Investigation of Hsp90C‐Terminal Inhibitors Containing Amide Bioisosteres},
  journal = {ChemMedChem},
  year = {2024},
  volume = {19},
  number = {24},
  doi = {10.1002/cmdc.202400418}
}
Kostenlos starten →